Contrast Reaction Treatment
| Severity | Signs / Symptoms | Treatment |
|---|---|---|
| Mild | Limited urticaria, pruritus, mild nausea/vomiting, flushing, headache, dizziness, single episode of emesis | Observe and reassure · Diphenhydramine 25–50 mg PO/IM/IV (optional, for comfort) |
| Moderate | Diffuse urticaria, facial or laryngeal edema (mild), bronchospasm (mild–moderate), tachycardia or bradycardia without hypotension | Diphenhydramine 25–50 mg IV · O₂ 6–10 L/min · Bronchospasm: albuterol MDI 2–3 puffs · IV access; continuous monitoring · Consider epinephrine if progressing |
| Severe — Anaphylaxis | Severe bronchospasm, laryngeal edema/stridor, profound hypotension, loss of consciousness, cardiac arrest | Epinephrine 0.3–0.5 mg IM (1:1,000) to lateral thigh · Call code / RRT · O₂ · Large-bore IV + NS bolus 1–2 L · Repeat epi q5–15 min PRN · Diphenhydramine 50 mg IV · Corticosteroids (delayed benefit only) |
| Vasovagal | Bradycardia + hypotension + pallor/diaphoresis — without urticaria (key distinction from anaphylaxis) | Trendelenburg position · NS bolus · Atropine 0.6–1.0 mg IV if bradycardia persists; may repeat (max 3 mg) · O₂ |
Epinephrine Dosing
- Adults: 0.3–0.5 mg IM (1:1,000 = 1 mg/mL) to outer thigh; may repeat q5–15 min
- Pediatric: 0.01 mg/kg IM (max 0.5 mg) · ~0.15 mg if <30 kg · ~0.3 mg if ≥30 kg
- EpiPen: 0.3 mg adult / 0.15 mg pediatric auto-injector
- Cardiac arrest: Epinephrine 1 mg IV (1:10,000) per ACLS protocol
- β-blocker patients with refractory reaction: Glucagon 1–5 mg IV, then 5–15 mcg/min infusion
Targeted Treatment by Symptom
| Symptom | Treatment |
|---|---|
| Isolated bronchospasm | Albuterol MDI 2–4 puffs; if severe or not responding → epinephrine 0.3 mg IM |
| Isolated hypotension (no bradycardia) | Epinephrine 0.3–0.5 mg IM; NS 1–2 L IV bolus; Trendelenburg |
| Diffuse urticaria | Diphenhydramine 25–50 mg IV/IM; epinephrine IM if rapidly progressing |
| Laryngeal edema / stridor | Epinephrine 0.3–0.5 mg IM immediately; O₂; prepare for intubation |
| Seizure | Protect airway; benzodiazepine (diazepam 5–10 mg IV or lorazepam 2–4 mg IV) |
| Pulmonary edema | O₂; furosemide 40 mg IV; morphine 2–4 mg IV; upright position; consider CPAP |
Reaction Risk Factors
- Prior allergic-like reaction to same contrast class → ~5× increased risk of subsequent reaction
- Multiple unrelated allergies (food, environmental) → 2–3× increased risk vs. general population
- Shellfish or iodine allergy → no greater risk than other allergies (prior dogma is explicitly rejected by ACR)
- Asthma / atopy (no prior contrast reaction) → modest increase; individualize
Premedication Guidelines (ACR)
Indication: Prior allergic-like or unknown-type reaction to the same class of contrast agent (iodinated or GBCA) — any severity. Premedication reduces but does not eliminate risk; breakthrough reactions occur in ~10–17% of premedicated patients.
| Regimen | Protocol | When to Use |
|---|---|---|
| Standard (13–7–1 h) | Prednisone 50 mg PO at 13 h, 7 h, and 1 h before contrast + Diphenhydramine 50 mg IV/IM/PO 1 h before | Elective studies with ≥13 h preparation time; preferred regimen |
| Methylprednisolone (12–2 h) | Methylprednisolone 32 mg PO at 12 h and 2 h before contrast ± Diphenhydramine 50 mg PO/IV 1 h before (optional) | Equally effective alternative; useful when prednisone unavailable or for cost |
| Emergency (<5 h available) | Methylprednisolone 40 mg IV (or hydrocortisone 200 mg IV) q4h until procedure + Diphenhydramine 50 mg IV 1 h before | Urgent/emergent contrast needed; less effective; document risk/benefit discussion |
Who Needs Premedication
| Scenario | Premedication? |
|---|---|
| Prior allergic-like reaction to same contrast class | Yes — standard or emergency regimen |
| Prior physiologic reaction only (nausea, warmth, flushing) | No — not indicated |
| Shellfish or iodine allergy | No — not higher risk than general population (common misconception) |
| Asthma / atopy (no prior contrast reaction) | Consider — elevated baseline risk; individualize |
| Prior reaction to a different contrast class | No — class-specific risk; iodinated ≠ GBCA |
| β-blocker use | Note — may blunt epinephrine; have glucagon available if reaction occurs |
Breakthrough reactions still occur despite premedication (~10–17%). Breakthrough reactions tend to mirror the index reaction in severity.
Iodinated Contrast & Renal Function
CA-AKI replaces "CIN": The ACR uses contrast-associated AKI (CA-AKI) and contrast-induced AKI (CI-AKI) rather than "contrast-induced nephropathy (CIN)," recognizing that post-contrast AKI is not always causally related to contrast. Absolute risk is <1% for eGFR ≥30 with modern low-osmolality agents.
| eGFR (mL/min/1.73m²) | IV Iodinated Contrast | Prehydration |
|---|---|---|
| ≥30 | May give; not at increased risk of CA-AKI; routine prophylaxis not indicated | Not required |
| 15–29 | Use with caution; weigh alternatives for elective studies; document discussion | Recommended: NS 1–3 mL/kg/h starting 1 h before, continuing 3–12 h after |
| <15 or dialysis | May give — contrast is NOT contraindicated even in ESRD/dialysis patients | Not needed in ESRD on regular dialysis; no urgent change in dialysis timing required |
| AKI / unstable renal function | Treat as eGFR <30; defer elective contrast if possible | Consider prehydration; reassess after renal function stabilizes |
Pre-contrast eGFR screening — targeted, not universal (ACR): Routine creatinine/eGFR for all contrast patients is no longer recommended. Screen only patients with risk factors for underlying CKD: known or suspected CKD, history of AKI, dialysis, renal transplant, single kidney, kidney surgery or cancer, history of albuminuria. Patients without these risk factors do not require pre-contrast renal labs.
Metformin Management (ACR 2025)
| eGFR / Clinical Context | Action |
|---|---|
| ≥30, no AKI | Continue metformin — no hold required before or after iodinated contrast |
| <30 or known AKI | Hold metformin at the time of or before contrast; restart 48 h later only after confirming renal function is stable |
| Arterial catheter studies (any eGFR) | Hold metformin regardless of eGFR (risk of renal artery emboli); restart after 48 h with confirmed stable renal function |
| Emergent contrast, eGFR unknown | Administer contrast; hold metformin after; check renal function at 48 h before restarting |
Note: Mechanism: contrast → CA-AKI → ↓ metformin clearance → metformin accumulation → lactic acidosis. Prior guidance to hold for eGFR 30–44 is no longer recommended.
Factors That Increase CA-AKI Risk
- Strongest risk factors: Pre-existing CKD (eGFR <30), diabetes with CKD, volume depletion, concomitant nephrotoxins (NSAIDs, aminoglycosides)
- Contrast-related factors: High-osmolality agents (HOCM) > low-osmolality (LOCM); larger contrast volume; repeat doses within 24–48 h
- Weak/debated risk factors: CHF, hypertension, age >75, single kidney — only clinically meaningful in the context of reduced eGFR
Gadolinium-Based Contrast & NSF
Nephrogenic Systemic Fibrosis (NSF): Rare fibrosing disorder (skin, joints, organs) associated with GBCA exposure in severe renal impairment. All confirmed NSF cases have been associated with Group I (high-risk linear) agents. No confirmed NSF cases have been reported with Group II agents at standard clinical doses.
2025 ACR GBCA Classification Update: All modern agents in current routine US use are now classified as Group II (low/negligible NSF risk). Group I agents are essentially withdrawn from the US market. Gadopiclenol (Elucirem/Vueway) is provisionally designated Group III pending broader safety data in high-risk populations.
| GBCA Group | Agents | NSF Risk |
|---|---|---|
| Group I — High Risk (linear, essentially withdrawn from US) | Gadodiamide (Omniscan) · Gadopentetate dimeglumine (Magnevist) · Gadoversetamide (OptiMARK) | High — all confirmed NSF cases; avoid in eGFR <30 or AKI |
| Group II — Low / Negligible Risk (macrocyclic preferred) | Macrocyclic (preferred): Gadobutrol (Gadavist) · Gadoteric acid/gadoterate meglumine (Dotarem, Clariscan) · Gadoteridol (ProHance). Linear, protein-binding: Gadobenate dimeglumine (MultiHance) · Gadoxetate disodium (Eovist/Primovist) | Low/negligible — 0 confirmed NSF cases at standard doses; eGFR screening optional |
| Group III — Provisional | Gadopiclenol (Elucirem / Vueway) | Presumed low; provisionally classified pending broader safety data in CKD stage 4–5 |
GBCA by eGFR
| eGFR | Group II (macrocyclic preferred) | Group I (avoid; largely unavailable) |
|---|---|---|
| ≥30 | May give at standard dose; no special precautions; eGFR screening optional | Group I: strongly avoid |
| 15–29 | May give; use lowest effective dose; document risk/benefit; eGFR screening recommended | Group I: avoid |
| <15 (non-dialysis) | Use only if clinically essential; lowest effective dose; macrocyclic strongly preferred | Group I: contraindicated |
| Dialysis (ESRD) | May use with caution; prompt post-injection dialysis not required but may reduce Gd exposure if clinically convenient | Group I: contraindicated |
| AKI | Treat as eGFR <30 until resolved; defer elective GBCA if possible; macrocyclic preferred if needed urgently | Group I & II linear: avoid |
Gadolinium retention (all agents): Small quantities of Gd deposit in brain (dentate nucleus, globus pallidus), bone, and skin with repeated doses. Macrocyclic agents show significantly less deposition than linear agents. No established adverse clinical effects in patients with normal renal function.
Contrast Extravasation
Most contrast extravasations are minor and resolve without intervention. Iodinated contrast and GBCAs are both low-osmolality and generally well-tolerated in soft tissue. The key concern is compartment syndrome — rare but limb-threatening.
| Volume | Initial Management | Disposition |
|---|---|---|
| Minor (<10 mL) | Elevate extremity · Cold compress 15–20 min q1–4h × 24 h · Reassure patient | Observe 30 min; discharge with return precautions if no progression |
| Moderate (10–30 mL) | Elevate extremity · Cold compress · Monitor for compartment syndrome signs × 2–4 h | Return precautions; follow-up call at 24 h; low threshold for ED evaluation |
| Large (>30 mL) or High-Risk Site | Elevate extremity · Cold compress · Urgent surgery/plastics consultation | Admit or ED for observation; possible surgical irrigation or fasciotomy |
Signs of compartment syndrome — requires urgent surgical consultation:
- Increasing pain or tightness disproportionate to the injection site
- Skin blistering, bullae, or visible skin breakdown
- Paresthesia, numbness, or decreased sensation distal to site
- Decreased capillary refill, pallor, or pulselessness distally
High-risk extravasation characteristics: distal site (hand, foot, antecubital fossa) · volume >50 mL · HOCM agents · impaired arterial circulation / peripheral vascular disease · immunocompromised or lymphedematous limb.
| Agent Type | Tissue Injury Profile |
|---|---|
| Low-osmolality iodinated (LOCM) | Mild — osmolality near physiologic; generally well-tolerated in soft tissue |
| High-osmolality iodinated (HOCM) | Higher injury risk — hyperosmolar; causes more osmotic tissue damage; rarely used today |
| Gadolinium (GBCA) | Mild — low-osmolality, similar to LOCM; same management protocol applies |
Contrast Media & Breastfeeding
2024 ACR Update — major change: Cessation of breastfeeding after iodinated or gadolinium-based contrast is no longer recommended. Prior guidance to "pump and dump" for 24–48 hours is considered overly conservative and is not supported by current evidence.
| Agent Class | Recommendation | Rationale |
|---|---|---|
| Iodinated contrast (LOCM) | Continue breastfeeding — no interruption needed | Only ~1% of administered contrast is excreted into breast milk; of that, oral bioavailability to infant is negligible. No documented harm to breastfed infants. |
| Gadolinium (GBCA) | Continue breastfeeding — no interruption needed | Amount excreted into breast milk is minimal; absorbed by infant GI tract in clinically insignificant quantities. Macrocyclic agents have lowest tissue retention profile. |
If the patient prefers to pause breastfeeding: A 24-hour interruption remains an acceptable option if the patient and physician jointly decide this is appropriate. This should be a shared decision — not a routine requirement.
Contrast Media in Pregnancy
| Agent Class | ACR Guidance | Key Points |
|---|---|---|
| Iodinated contrast (IV) | Do not routinely withhold when clinically indicated | Risk to fetus is considered minimal at standard doses · Transplacental passage of free iodine is theoretical; neonatal thyroid function should be checked if given during pregnancy · Benefit to maternal diagnosis typically outweighs fetal risk |
| Gadolinium (GBCA) | Use only when benefit clearly outweighs risk; more conservative approach than iodinated contrast | Free gadolinium ions cross placenta and recirculate in amniotic fluid — prolonged fetal exposure possible · Animal data shows teratogenicity at high/repeated doses, not at standard clinical doses · Document clinical rationale and informed consent · Use lowest effective dose; macrocyclic preferred |
| Oral / rectal iodinated contrast | Generally safe — minimal systemic absorption | Enteral agents are not appreciably absorbed; fetal exposure is negligible |
Routine pregnancy screening before contrast in women of childbearing age is not recommended by ACR.
Fasting Before Contrast
ACR position: Fasting is not required prior to IV administration of iodinated contrast (CT) or gadolinium-based contrast (MRI) using modern nonionic, low-osmolality agents.
| Situation | Fasting Required? |
|---|---|
| Routine CT with IV iodinated contrast (LOCM) | No — not required |
| Routine MRI with IV gadolinium (GBCA) | No — not required |
| Procedure requiring sedation or general anesthesia | Yes — standard anesthesia NPO guidelines apply (independent of contrast) |
| Abdominal imaging requiring bowel preparation for diagnostic quality | Varies — fasting may improve image quality; not a contrast safety requirement |
Evidence: A meta-analysis of 308,013 patients found no difference in nausea rates between fasting and non-fasting groups (4.6% vs. 4.6%). A separate review of 13 studies (2,001 patients) found zero cases of aspiration pneumonia attributable to iodinated contrast.
References: ACR Manual on Contrast Media (2025). Davenport MS et al. Use of IV Iodinated Contrast in Patients with Kidney Disease: ACR/NKF Consensus Statements. Radiology. 2020;294(3):660–668. Weinreb JC et al. Use of IV GBCA in Patients with Kidney Disease: ACR/NKF Consensus Statements. Radiology. 2021;298(1):28–35.